Ovarian Cancer Drugs: Current Standards and Future Perspectives
Ovarian
cancer is one of the most common type of cancer in women that mainly affects
the women who have been through menopause. The common symptoms of ovarian
cancer includes bloating, pelvic or abdominal pain, fatigue, upset stomach,
back pain and others. The prime cause of ovarian cancer is unknown however,
women are at high risk of getting it being over 50 years of age and have a
family history for the disease.
The ovarian
cancer drugs market is anticipated to grow in the forecast, owing to the
factors such as increasing incidence of ovarian cancer, advancements in cancer
therapies and others. In addition, several initiatives undertaken by various
government and non-government organizations for research and investment into
ovarian cancer drugs therapeutics is expected to offer significant growth
opportunities in the market during the forecast period.
The reports
cover key developments in the ovarian cancer drugs market as organic and
inorganic growth strategies. Various companies are focusing on organic growth
strategies such as product launches, product approvals and others such as
patents and events. Inorganic growth strategies activities witnessed in the
market were acquisitions and partnership & collaborations. These activities
have paved way for expansion of business and customer base of market players.
The report
also includes the profiles of key ovarian cancer drugs market companies along
with their SWOT analysis and market strategies. In addition, the report focuses
on leading industry players with information such as company profiles,
components and services offered, financial information of last 3 years, key
development in past five years.
Most Prominent Key Players Operating in this Study Include,
1. Allergan
2. Astrazeneca
3. F.hoffmann La Roche, Ltd.
4. Pfizer, Inc.
5. Merck Kgaa
6. Syndax
7. Clovis Oncology
8. Boehringer Ingelheim International Gmbh
9. Tesaro, Inc.
10. Amgen Inc.
Comments
Post a Comment